Skip to main content
OpenTrials
Completed

NCT Number: NCT00740324

Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men

The purpose of this study is to evaluate the safety and efficacy of the additional administration of scopolamine butylbromide, glucagon or NPO-11 following a single intragastric dose of NPO-11 during endoscopy in healthy adult men. The safety will be evaluated based on adverse events and adverse drug reactions (ADRs) observed with NPO-11 + scopolamine butylbromide or glucagon, and following additional administration of NPO-11. The efficacy will be evaluated based on changes in the frequency of gastric peristalsis classification after the initial dose and the additional dose, and on the presence or absence of gastric peristalsis at each evaluation point.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

35 year–65 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 3

Primary location

Tokyo, Japan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy adult male volunteers who meet all the following criteria will be enrolled in the study. Subjects have to provide written informed consent for voluntary participation in the study.

  • Volunteers who are in good health as confirmed by the investigator or subinvestigator
  • Volunteers (age from 35 to less than 65 years old at the time of consent)

Exclusion criteria

Volunteers who meet any of the following criteria will be excluded from the study.

  • Volunteers with any clinically significant symptoms, physical findings or laboratory values at screening visit which are considered unsuitable for participation in the study in the investigator's or subinvestigator's opinion
  • Volunteers with a history of surgery in the upper gastrointestinal tract
  • Volunteers with a history of shock or hypersensitivity to l-menthol or peppermint oil (mint oil)
  • Volunteers with a history of shock or hypersensitivity to scopolamine butylbromide, glucagon, lidocaine hydrochloride or heparin sodium
  • Volunteers who are contraindicated for administration of scopolamine butylbromide or glucagon in the investigator's or subinvestigator's opinion based on health interview
  • Volunteers who have been exposed to NPO-11
  • Volunteers who have received other investigational drugs within four months before consent or who are participating in other clinical studies
  • Volunteers otherwise ineligible for participation in the study in the investigator's or subinvestigator's opinion

Treatment and study plan

NPO-11

Drug

20 mg butylscopolammonium bromide after administration of NPO-11

Primary outcomes

  1. [Safety] (Evaluation by investigator or subinvestigator) Adverse events and ADRs observed between administration and 7 ± 3 days after administration

    Time frame: 7 ± 3 days after administration

Secondary outcomes

  1. [Efficacy] (Central evaluation by independent evaluator) (1) Change in the frequency of gastric peristalsis classification (2) Presence or absence of gastric peristalsis at each evaluation point

    Time frame: each evaluation point

Sponsors and collaborators

Lead sponsor

Nihon Pharmaceutical Co., Ltd

Industry

Registry information

Official study title

Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men During Endoscopy

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Aug 22, 2008
Registry last updated
Nov 9, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.